In summary, by comparing the comethylation status of OSR2, VAV3, and PPFIA3 in tissue and serum samples between GC patients and healthy individuals, we found that those three genes have a relatively high sensitivity and specificity and therefore may be used as a biomarker for noninvasive screening of GC. This evidence concerns the gene VAV3 and gastric cancer.